With PI3K-activated DLBCL patients (group B in our cohort) manifesting inferior survival outcome, we wonder whether inhibition of the PI3K signaling activity could also alter the phenotypic characteristics of DLBCL. This evidence concerns the gene PIK3CD and diffuse large B-cell lymphoma.